GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Dose Titration of Recombinant Factor Viia Using
Thromboelastograph Monitoring: A Case Report
and Brief Review

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

>>
J Extra Corpor Technol. 2006 Sep;38(3):254-9.

Trowbridge CC, Stammers AH, Ciccarelli N, Klayman M.

Department of Surgery, Division of Perfusion Services, Geisinger Medical Center, Perfusion Services, 20-15 100 N. Academy Avenue, Danville, PA 17821, USA.

The administration of recombinant factor VIIa (rFVIIa) is complicated by a wide inter-subject variation in response, a short half-life, evolving indications for use, and the absence of a test that has been shown to correlate with clinical effect.

This report describes a method used to titrate rFVIIa to thromboelastography (TEG) parameters in a difficult to manage hemophilic patient with high titer inhibition to factor VIII. The current concepts of monitoring rFVIla administration in hemophiliacs and uncontrolled hemorrhage in cardiac surgery are briefly reviewed.
<<